| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA0707534 |
| P698 | PubMed publication ID | 18480205 |
| P50 | author | Thorsten Steiner | Q94659717 |
| Stephan A. Mayer | Q111584599 | ||
| P2093 | author name string | Stephen Davis | |
| Joseph Broderick | |||
| Brett E Skolnick | |||
| FAST Trial Investigators | |||
| Kamilla Begtrup | |||
| Michael N Diringer | |||
| Nikolai C Brun | |||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2127-2137 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage | |
| P478 | volume | 358 |
| Q35019877 | 17β-Estradiol attenuates hematoma expansion through estrogen receptor α/silent information regulator 1/nuclear factor-kappa b pathway in hyperglycemic intracerebral hemorrhage mice |
| Q22241919 | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q41137868 | A prototype device for non-invasive continuous monitoring of intracerebral hemorrhage |
| Q56888033 | Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data |
| Q45838467 | Active extravasation of contrast within the hemorrhage (spot sign): a multidetector computed tomography finding that predicts growth and a worse prognosis in non-traumatic intracerebral hemorrhage |
| Q42697695 | Acute hypertensive response in patients with intracerebral hemorrhage pathophysiology and treatment |
| Q38065699 | Acute management of bleeding in patients on novel oral anticoagulants. |
| Q38005465 | Acute stroke management in patients taking dabigatran. |
| Q85042844 | Acute treatment of hypertensive intracerebral hemorrhage |
| Q34274601 | Advances in spontaneous intracerebral haemorrhage |
| Q37793839 | Advances in the management of intracerebral hemorrhage |
| Q38110476 | Advances in the management of intracerebral hemorrhage |
| Q38430484 | Alternative clinical trial design in neurocritical care |
| Q33438542 | An emerging role of mast cells in cerebral ischemia and hemorrhage |
| Q33753097 | Anemia is an independent prognostic factor in intracerebral hemorrhage: an observational cohort study |
| Q90205678 | Anesthetic considerations for extracranial injuries in patients with associated brain trauma |
| Q83291458 | Anti-adrenergic medications and edema development after intracerebral hemorrhage |
| Q38013666 | Anticoagulation-related intracranial hemorrhages |
| Q35922150 | Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale |
| Q35208004 | Antiplatelet pretreatment does not increase hematoma volume in experimental intracerebral hemorrhage |
| Q35992110 | Apolipoprotein E genotype predicts hematoma expansion in lobar intracerebral hemorrhage |
| Q41657712 | Applicability of Clinical Trials in an Unselected Cohort of Patients With Intracerebral Hemorrhage |
| Q84090377 | Aspirin use or reduced platelet activity predicts craniotomy after intracerebral hemorrhage |
| Q39669954 | Association Between Hypodensities Detected by Computed Tomography and Hematoma Expansion in Patients With Intracerebral Hemorrhage |
| Q34447650 | Association Factors for CT Angiography Spot Sign and Hematoma Growth in Korean Patients with Acute Spontaneous Intracerebral Hemorrhage : A Single-Center Cohort Study |
| Q92680048 | Association between Non-Alcoholic Fatty Liver Disease and Intracerebral Hemorrhage |
| Q81771623 | Association between disability measures and short-term health care costs following intracerebral hemorrhage |
| Q91972057 | Association of Intensive Blood Pressure Reduction With Risk of Hematoma Expansion in Patients With Deep Intracerebral Hemorrhage |
| Q38813005 | Association of Key Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease With Hematoma Volume and Expansion in Patients With Lobar and Deep Intracerebral Hemorrhage |
| Q38840375 | Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammation |
| Q46135507 | Astroglial proteins as diagnostic markers of acute intracerebral hemorrhage-pathophysiological background and clinical findings |
| Q38783052 | Attitudes of Patients and Relatives Toward Disability and Treatment in Malignant MCA Infarction |
| Q52981914 | Audit of CT reporting standards in cases of intracerebral haemorrhage at a comprehensive stroke centre in Australia. |
| Q28756698 | Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis--funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy |
| Q83551195 | Beyond therapeutic nihilism? The neurosurgical treatment of intracerebral hemorrhage |
| Q35729723 | Biomarkers in neurocritical care |
| Q92069627 | Blood Transfusion in the 21st Century |
| Q79715534 | Blood pressure reduction for acute intracerebral hemorrhage: how low can you go? |
| Q35635606 | Blood pressure reduction, decreased diffusion on MRI, and outcomes after intracerebral hemorrhage |
| Q38298655 | Blood transfusion practices in neuroanaesthesia |
| Q27010013 | Blood-brain barrier breakdown in acute and chronic cerebrovascular disease |
| Q33818147 | Brain perihematoma genomic profile following spontaneous human intracerebral hemorrhage |
| Q37348664 | C1q/Tumor Necrosis Factor-Related Protein-3 Attenuates Brain Injury after Intracerebral Hemorrhage via AMPK-Dependent Pathway in Rat |
| Q47165301 | CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. |
| Q42426171 | CT Angiography Spot Sign, Hematoma Expansion, and Outcome in Primary Pontine Intracerebral Hemorrhage |
| Q37304873 | CT angiography for intracerebral hemorrhage does not increase risk of acute nephropathy |
| Q48493679 | CT imaging for long-term functional outcome after spontaneous intracerebral haemorrhage: A 3-year follow-up study. |
| Q38057670 | CT perfusion spot sign improves sensitivity for prediction of outcome compared with CTA and postcontrast CT. |
| Q37000461 | CTA spot sign predicts hematoma expansion in patients with delayed presentation after intracerebral hemorrhage |
| Q40968630 | Calibrated automated thrombography for monitoring coagulation function in patients with intracerebral haemorrhage |
| Q53363030 | Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India. |
| Q46160374 | Case Report: Apixaban-Associated Gluteal Artery Extravasation Reversed With PCC3 Without FFP. |
| Q48035381 | Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions. |
| Q37978627 | Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage |
| Q47723442 | Challenges for intraventricular hemorrhage research and emerging therapeutic targets |
| Q36907362 | Childhood hemorrhagic stroke: an important but understudied problem |
| Q36307975 | Classification of Different Degrees of Disability Following Intracerebral Hemorrhage: A Decision Tree Analysis from VISTA-ICH Collaboration. |
| Q36428879 | Clinical applications of the computed tomography angiography spot sign in acute intracerebral hemorrhage: a review |
| Q37176741 | Clinical nihilism in neuroemergencies |
| Q39367698 | Clinical re-evaluation of removing blood stasis therapy in treating acute intracerebral hemorrhage safety and efficacy: a protocol for a randomized, controlled, multicenter study (CRRICH Trial). |
| Q38117418 | Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications |
| Q37106076 | Clinical review: Critical care management of spontaneous intracerebral hemorrhage |
| Q26830409 | Clinical review: Traumatic brain injury in patients receiving antiplatelet medication |
| Q38005904 | Clinical syndromes and management of intracerebral hemorrhage |
| Q37906399 | Clinical trial design in the neurocritical care unit |
| Q41298252 | Clotting factor product administration and same-day occurrence of thrombotic events, as recorded in a large healthcare database during 2008-2013. |
| Q39898890 | Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage. |
| Q51136017 | Coagulation factor VIIa (recombinant) in nonhemophilic patients requiring neurosurgery. |
| Q48092485 | Combination of Intra-Hematomal Hypodensity on CT and BRAIN Scoring Improves Prediction of Hemorrhage Expansion in ICH. |
| Q35126229 | Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product |
| Q33637412 | Comparison of hematoma shape and volume estimates in warfarin versus non-warfarin-related intracerebral hemorrhage |
| Q37968783 | Complications of intracerebral haemorrhage |
| Q37867279 | Controversies of anticoagulation reversal in life-threatening bleeds |
| Q91816674 | Correlation between Spot Sign and Intracranial Hemorrhage Expansion on Dual-Phase CT Angiography |
| Q40415916 | Current treatment options for intracerebral hemorrhage |
| Q53094928 | DESTINY-S: attitudes of physicians toward disability and treatment in malignant MCA infarction. |
| Q35226978 | Dabigatran etixilate and traumatic brain injury: Evolving anticoagulants require evolving care plans |
| Q50860323 | Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. |
| Q92535356 | Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial |
| Q33827840 | Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes |
| Q54051893 | Delayed neurological deterioration in ICH due to cerebral infarction. |
| Q36914604 | Detrimental effects of leptin on intracerebral hemorrhage via the STAT3 signal pathway |
| Q43762347 | Discharge destination as a surrogate for Modified Rankin Scale defined outcomes at 3- and 12-months poststroke among stroke survivors |
| Q30502787 | Dynamic 'Spot Sign' Resolution following INR Correction in a Patient with Warfarin-Associated Intracerebral Hemorrhage |
| Q36324926 | Dynamic nature of the CT angiographic "spot sign". |
| Q37895390 | Early management of stroke patients in the emergency department |
| Q84752792 | Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage |
| Q59813639 | Effect of Pretreatment with the NADPH Oxidase Inhibitor Apocynin on the Therapeutic Efficacy of Human Placenta-Derived Mesenchymal Stem Cells in Intracerebral Hemorrhage |
| Q50603071 | Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center. |
| Q45854165 | Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial |
| Q91440507 | Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial |
| Q54917660 | Efficacy of Chitosan-Based Dressing for Control of Bleeding in Excisional Wounds. |
| Q38607612 | Efficacy of Laropiprant in Minimizing Brain Injury Following Experimental Intracerebral Hemorrhage. |
| Q38599754 | Emergency Neurological Life Support: Intracerebral Hemorrhage |
| Q48111775 | Emergency Neurological Life Support: Intracerebral Hemorrhage |
| Q38599737 | Emergency Neurological Life Support: Pharmacotherapy |
| Q38042353 | Emergency neurological life support: intracerebral hemorrhage. |
| Q93585151 | Enrollment of Research Subjects through Telemedicine Networks in a Multicenter Acute Intracerebral Hemorrhage Clinical Trial: Design and Methods |
| Q34300317 | Enrollment of research subjects through telemedicine networks in a multicenter acute intracerebral hemorrhage clinical trial: design and methods |
| Q45862479 | Ethics & evidence in medical debates: the case of recombinant activated factor VII. |
| Q38007885 | Etiologies of intracerebral hematomas |
| Q92426236 | European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage |
| Q37017398 | European research priorities for intracerebral haemorrhage |
| Q61812227 | Evaluating the predictive capabilities of haematoma expansion scores in patients with acute intracerebral haemorrhage: protocol for a scoping review |
| Q37684839 | Evidence-based neurocritical care |
| Q90328636 | Evolution of Traumatic Parenchymal Intracranial Hematomas (ICHs): Comparison of Hematoma and Edema Components |
| Q38669629 | Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials |
| Q35534164 | Experimental intracerebral hemorrhage: avoiding pitfalls in translational research |
| Q88687080 | Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis |
| Q31160762 | Factors associated with early deterioration after spontaneous intracerebral hemorrhage: a systematic review and meta-analysis |
| Q33159285 | Fibrinolysis for acute pulmonary embolism |
| Q37623707 | Frequency of hematoma expansion after spontaneous intracerebral hemorrhage in children |
| Q39683385 | Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial |
| Q35582407 | Full medical support for intracerebral hemorrhage. |
| Q35060644 | Gender and age interact to affect early outcome after intracerebral hemorrhage |
| Q27313248 | Genetic deletion of the prostaglandin E2 E prostanoid receptor subtype 3 improves anatomical and functional outcomes after intracerebral hemorrhage |
| Q84774397 | Geriatric care in the surgical intensive care unit |
| Q38682353 | Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. |
| Q35711431 | Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association |
| Q24240451 | Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage |
| Q24240692 | Haemostatic drugs for acute traumatic brain injury |
| Q24188122 | Haemostatic drugs for traumatic brain injury |
| Q24240304 | Haemostatic drugs for traumatic brain injury |
| Q52583006 | Haemostatic therapies for acute spontaneous intracerebral haemorrhage. |
| Q88736307 | Haemostatic treatment for intracerebral haemorrhage |
| Q38734794 | Hematoma Expansion following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation. |
| Q88084069 | Hematoma Heterogeneity on Noncontrast Computed Tomography Predicts Intracerebral Hematoma Expansion: A Meta-Analysis |
| Q90059386 | Hematoma enlargement characteristics in deep versus lobar intracerebral hemorrhage |
| Q37095550 | Hematoma expansion following acute intracerebral hemorrhage |
| Q37118036 | Hematoma volume measurement in gradient echo MRI using quantitative susceptibility mapping |
| Q39209982 | Hemostasis in Intracranial Hemorrhage |
| Q37598917 | High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods |
| Q44610130 | High serum levels of growth factors are associated with good outcome in intracerebral hemorrhage. |
| Q55508260 | Human Placenta-Derived Mesenchymal Stem Cells Reduce Mortality and Hematoma Size in a Rat Intracerebral Hemorrhage Model in an Acute Phase. |
| Q57168432 | Impact of Recent Studies for the Treatment of Intracerebral Hemorrhage |
| Q90097059 | Impact of Spot Sign Etiology in Supratentorial Intracerebral Hemorrhage on Outcomes of Endoscopic Surgery |
| Q38582378 | Impact of an innovative blood factor stewardship program on drug expense and patient care |
| Q37794843 | Impact of intraventricular hemorrhage upon intracerebral hematoma expansion |
| Q38170056 | Improving acute stroke management with computed tomography perfusion: a review of imaging basics and applications |
| Q37599918 | Intensive care management of acute stroke: general management |
| Q37434824 | Interleukin-23 Secreted by Activated Macrophages Drives γδT Cell Production of Interleukin-17 to Aggravate Secondary Injury After Intracerebral Hemorrhage |
| Q34045411 | Interpretation and Implementation of Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT II). |
| Q36543599 | Interventional Algorithms for the Control of Coagulopathic Bleeding in Surgical, Trauma, and Postpartum Settings: Recommendations From the Share Network Group |
| Q90464542 | Interventional Ultrasound Assisted Early Local Hemostatic Drug Therapy in Traumatic Intracerebral Hemorrhage |
| Q28073307 | Intracerebral Hemorrhage: Perihemorrhagic Edema and Secondary Hematoma Expansion: From Bench Work to Ongoing Controversies |
| Q33442365 | Intracerebral haemorrhage |
| Q36984232 | Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies |
| Q57482499 | Intracerebral haemorrhage: current approaches to acute management |
| Q37448194 | Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. |
| Q89910624 | Intracerebral haemorrhage: no good treatment but treatment helps |
| Q43574054 | Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study |
| Q38113483 | Intracerebral hemorrhage in patients receiving oral anticoagulation therapy |
| Q37809772 | Intracerebral hemorrhage specific intensity of care quality metrics |
| Q42043560 | Intracerebral hemorrhage: a multimodality approach to improving outcome |
| Q38035818 | Intracerebral hemorrhage: a review of coagulation function. |
| Q83549183 | Intracerebral hemorrhage: a transition phase toward better prognosis |
| Q86924887 | Intracerebral hemorrhage: clinical overview and pathophysiologic concepts |
| Q35988434 | Intracerebral hemorrhage: toward physiological imaging of hemorrhage risk in acute and chronic bleeding |
| Q26825331 | Intracranial hemorrhage |
| Q82946736 | Intracranial hemorrhage |
| Q34397257 | Intracranial hemorrhage in adult patients with hematological malignancies. |
| Q38805424 | Intracranial hemorrhage in cancer patients treated with anticoagulation |
| Q38005011 | Intracranial hemorrhage in patients with cancer. |
| Q34413685 | Intrastriatal injection of autologous blood or clostridial collagenase as murine models of intracerebral hemorrhage. |
| Q37347396 | Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage |
| Q35024385 | Invasive intracranial pressure monitoring is a useful adjunct in the management of severe hepatic encephalopathy associated with pediatric acute liver failure |
| Q52575597 | Iodine concentration: a new, important characteristic of the spot sign that predicts haematoma expansion. |
| Q45011676 | Is a sylvian fissure hematoma caused by leaking vessels? |
| Q42240430 | Ischemic stroke detection system with a computer-aided diagnostic ability using an unsupervised feature perception enhancement method |
| Q50084153 | Lateral Ventricular Volume Asymmetry Predicts Poor Outcome After Spontaneous Intracerebral Hemorrhage. |
| Q84338900 | Looking for the 'spot sign': enlightening the management of intracranial hemorrhage |
| Q96608526 | Low risk of traumatic intracranial hematoma expansion with factor Xa inhibitors without andexanet reversal |
| Q48626887 | Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0. |
| Q35974367 | Low-dose recombinant tissue-type plasminogen activator enhances clot resolution in brain hemorrhage: the intraventricular hemorrhage thrombolysis trial |
| Q28534475 | MRI-based analysis of intracerebral hemorrhage in mice reveals relationship between hematoma expansion and the severity of symptoms |
| Q91905443 | Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage |
| Q39103362 | Major publications in the critical care pharmacotherapy literature in 2015. |
| Q47125554 | Management of Spontaneous Intracerebral Hematoma |
| Q41531083 | Management of Spontaneous Intracerebral Hemorrhage |
| Q48235405 | Management of acute intracerebral haemorrhage - an update. |
| Q87831719 | Management of hepatic encephalopathy |
| Q24632452 | Management of intraventricular hemorrhage |
| Q38012660 | Management of ruptured brain arteriovenous malformations |
| Q37867296 | Management of spontaneous nontraumatic intracranial hemorrhage |
| Q36950625 | Management of thrombolysis-associated symptomatic intracerebral hemorrhage |
| Q38703600 | Managing Subdural Bleeding Associated With Rivaroxaban: A Series of 3 Cases |
| Q27001044 | Matrix metalloproteinases in human spontaneous intracerebral hemorrhage: an update |
| Q39010418 | Medical management of intracerebral haemorrhage. |
| Q38018892 | Medical versus surgical management of intracerebral hematomas |
| Q30448910 | Minimally invasive evacuation of spontaneous intracerebral hemorrhage using sonothrombolysis |
| Q43576819 | Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study. |
| Q38754285 | Mobile stroke units for prehospital thrombolysis, triage, and beyond: benefits and challenges. |
| Q27342135 | Modeling intracerebral hemorrhage growth and response to anticoagulation |
| Q85642622 | Modeling the pattern of contrast extravasation in acute intracerebral hemorrhage using dynamic contrast-enhanced MR |
| Q38462525 | Modulating the Immune Response Towards a Neuroregenerative Peri-injury Milieu After Cerebral Hemorrhage |
| Q87354355 | Neurocritical care in Germany: need for guidance |
| Q37806148 | Neurocritical care of a reperfused brain |
| Q38283522 | Neuroinflammation after intracerebral hemorrhage |
| Q43716090 | Neurological Impairment Among Survivors of Intracerebral Hemorrhage: The FAST Trial |
| Q37976564 | Neurological diseases in relation to the blood-brain barrier |
| Q37815043 | Neurological management of fulminant hepatic failure |
| Q26744214 | Neuroprotective effect of therapeutic hypothermia versus standard care alone after convulsive status epilepticus: protocol of the multicentre randomised controlled trial HYBERNATUS |
| Q38970532 | New Oral Anticoagulants and Their Reversal Agents |
| Q37598901 | New avenues for treatment of intracranial hemorrhage |
| Q37421521 | New drugs and devices from 2011 - 2012 that might change your practice |
| Q33392647 | New parenteral anticoagulants in development |
| Q24599047 | New trends in resuscitation |
| Q48465568 | No evidence or no alternative? Taking responsibility for off-label prescribing. |
| Q37807082 | Novel approaches to the treatment of intracerebral haemorrhage |
| Q34786006 | Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study |
| Q45865634 | Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report). |
| Q33571590 | Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records |
| Q38058551 | Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland. |
| Q43441422 | Off-protocol access to study therapies |
| Q55069307 | Opportunities in posthemorrhagic hydrocephalus research: outcomes of the Hydrocephalus Association Posthemorrhagic Hydrocephalus Workshop. |
| Q36294488 | Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices |
| Q37900185 | Oral anticoagulant-associated intracerebral hemorrhage |
| Q37632503 | Outcome of intracerebral haemorrhage patients pre-treated with statins |
| Q33542800 | PATCH: platelet transfusion in cerebral haemorrhage: study protocol for a multicentre, randomised, controlled trial |
| Q35663979 | Pediatric stroke: a review |
| Q30883837 | Performance characteristics of methods for quantifying spontaneous intracerebral haemorrhage: data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial |
| Q38762498 | Peri-Hemorrhagic Edema and Secondary Hematoma Expansion after Intracerebral Hemorrhage: From Benchwork to Practical Aspects |
| Q48226950 | Perihematomal Edema Expansion Rates and Patient Outcomes in Deep and Lobar Intracerebral Hemorrhage |
| Q90689971 | Perihematomal edema: Implications for intracerebral hemorrhage research and therapeutic advances |
| Q38668827 | Phantom-based standardization of CT angiography images for spot sign detection |
| Q55379791 | Pharmacokinetics of Human Red Blood Cell Microparticles Prepared Using High-Pressure Extrusion Method. |
| Q45067456 | Pharmacotherapy Pearls for Emergency Neurological Life Support |
| Q92510763 | Pooled analysis suggests benefit of catheter-based hematoma removal for intracerebral hemorrhage |
| Q34321852 | Pre-Hospital Glyceryl Trinitrate: Potential for Use in Intracerebral Hemorrhage |
| Q33862295 | Preclinical Studies and Translational Applications of Intracerebral Hemorrhage. |
| Q35914886 | Predicting Intracerebral Hemorrhage Growth With the Spot Sign: The Effect of Onset-to-Scan Time |
| Q34040461 | Predicting hematoma expansion after primary intracerebral hemorrhage |
| Q27008354 | Prediction and observation of post-admission hematoma expansion in patients with intracerebral hemorrhage |
| Q53171816 | Prediction of haematoma expansion with the CTA spot sign: a useful biomarker? |
| Q39642737 | Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study |
| Q64972320 | Prediction of hematoma expansion in spontaneous intracerebral hemorrhage using support vector machine. |
| Q41005980 | Prediction of intracerebral haemorrhage expansion with clinical, laboratory, pharmacologic, and noncontrast radiographic variables |
| Q37170225 | Predictors of 30-day mortality in patients with spontaneous primary intracerebral hemorrhage |
| Q37256620 | Predictors of hematoma volume in deep and lobar supratentorial intracerebral hemorrhage. |
| Q33911012 | Predictors of late neurological deterioration after spontaneous intracerebral hemorrhage |
| Q37666127 | Prehospital Systolic Hypertension and Outcomes in Patients with Spontaneous Intracerebral Hemorrhage |
| Q34360614 | Prehospital stroke care: new prospects for treatment and clinical research |
| Q44442118 | Prevalence and characterization of ECG abnormalities after intracerebral hemorrhage |
| Q55286673 | Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial. |
| Q34459723 | Progressing haemorrhagic stroke: categories, causes, mechanisms and managements |
| Q27015319 | Promoting blood circulation for removing blood stasis therapy for acute intracerebral hemorrhage: a systematic review and meta-analysis |
| Q46075730 | Prophylactic antiepileptic drug use is associated with poor outcome following ICH. |
| Q36331578 | Proposal for the Rapid Reversal of Coagulopathy in Patients with Nonoperative Head Injuries on Anticoagulants and/or Antiplatelet Agents: A Case Study and Literature Review |
| Q37393402 | Prospective validation of the ICH Score for 12-month functional outcome |
| Q36482822 | Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery |
| Q44226026 | Proteasome Inhibitor Reduces Astrocytic iNOS Expression and Functional Deficit after Experimental Intracerebral Hemorrhage in Rats |
| Q33430766 | Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting |
| Q37646452 | Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature |
| Q81657890 | Prothrombotic recombinant activated factor VII in intracerebral haemorrhage: FAST but not focused? |
| Q39352053 | Protocol for seizure prophylaxis following intracerebral hemorrhage study (SPICH): a randomized, double-blind, placebo-controlled trial of short-term sodium valproate prophylaxis in patients with acute spontaneous supratentorial intracerebral hemorr |
| Q34887388 | Quantifying the cost in power of ignoring continuous covariate imbalances in clinical trial randomization |
| Q53125191 | Quantitative CT densitometry for predicting intracerebral hemorrhage growth. |
| Q53223295 | Quantomo: validation of a computer-assisted methodology for the volumetric analysis of intracerebral haemorrhage. |
| Q38065635 | Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. |
| Q35998212 | Rate of Contrast Extravasation on Computed Tomographic Angiography Predicts Hematoma Expansion and Mortality in Primary Intracerebral Hemorrhage |
| Q26829915 | Rational Use of Recombinant Factor VIIa in Clinical Practice |
| Q93152657 | Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime) |
| Q52144837 | Re-exploring Tumor Necrosis Factor Alpha as a Target for Therapy in Intracerebral Hemorrhage. |
| Q92806830 | Reactive microglia and astrocytes in neonatal intraventricular hemorrhage model are blocked by mesenchymal stem cells |
| Q64079483 | Recent advances in spontaneous intracerebral hemorrhage |
| Q43212133 | Recently published papers: Renal replacement therapy: which route and how much? Intracerebral haematomas: does the size matter? Beta blockers and steroids: will we ever know? |
| Q33918017 | Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients |
| Q44637329 | Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events |
| Q38527508 | Recombinant activated factor VII: 30 years of research and innovation |
| Q34005911 | Recombinant factor VII is associated with worse survival in complex cardiac surgical patients |
| Q43453239 | Recombinant factor VIIa as last-resort treatment of desperate haemorrhage |
| Q24201292 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q24236583 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q24245204 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q45862972 | Recombinant factor VIIa for unlicensed indications--a definite No or a cautious Maybe in selected patients? |
| Q37710241 | Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants |
| Q34135771 | Recombinant factor VIIa use in patients presenting with intracranial hemorrhage |
| Q33756657 | Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation |
| Q45057598 | Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study |
| Q89801766 | Recommendations for Clinical Trials in ICH: The Second Hemorrhagic Stroke Academia Industry Roundtable |
| Q38106596 | Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban |
| Q36515685 | Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. |
| Q34681587 | Recruitment and retention of patients into emergency medicine clinical trials |
| Q38660256 | Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding |
| Q58735364 | Research Progress in Understanding the Relationship Between Heme Oxygenase-1 and Intracerebral Hemorrhage |
| Q33627679 | Resistant Hypertension after Hypertensive Intracerebral Hemorrhage Is Associated with More Medical Interventions and Longer Hospital Stays without Affecting Outcome |
| Q38602484 | Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors |
| Q49970899 | Reversal agents for non-vitamin K antagonist oral anticoagulants. |
| Q64983401 | Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage. |
| Q52892786 | Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular |
| Q91045479 | Risk predictors to limit neuronal loss after intracerebral haemorrhage |
| Q37705693 | Risks and benefits of CT angiography in spontaneous intracerebral hemorrhage |
| Q37618616 | Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage |
| Q47861634 | Role of prothrombin complex concentrate (PCC) in Acute Intracerebral Hemorrhage with Positive CTA spot sign: An institutional experience at a regional and state designated stroke center |
| Q42122092 | SCORE-IT: the Spot Sign score in restricting ICH growth─an Atach-II ancillary study. |
| Q64994908 | Safety and efficacy of herbal medicine for acute intracerebral hemorrhage (CRRICH): a multicentre randomised controlled trial. |
| Q40502468 | Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. |
| Q35449198 | Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage |
| Q37187480 | Safety issues and concerns for the neurological patient in the emergency department |
| Q46147769 | Scientific and logistical challenges in designing the CONTROL trial: recombinant factor VIIa in severe trauma patients with refractory bleeding |
| Q37740548 | Secondary Hematoma Expansion and Perihemorrhagic Edema after Intracerebral Hemorrhage: From Bench Work to Practical Aspects |
| Q85370189 | Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation? |
| Q33894276 | Small intracerebral haemorrhages are associated with less haematoma expansion and better outcomes. |
| Q38170031 | Sonothrombolysis: an emerging modality for the treatment of acute ischemic and hemorrhagic stroke |
| Q34654443 | Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". |
| Q34422390 | Spot sign on 90-second delayed computed tomography angiography improves sensitivity for hematoma expansion and mortality: prospective study |
| Q28066262 | Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran |
| Q51279659 | Statistical analysis plan for the second INTEnsive blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT2): a large-scale investigation to solve longstanding controversy over the most appropriate management of elevated blood pressure |
| Q97546855 | Stroke |
| Q84607710 | Stroke. 'Spotting' patients at the highest risk of hematoma growth |
| Q84189840 | Stroke: is spot sign the answer for intracerebral haemorrhage? |
| Q33392842 | Stroke: success for extending acute treatment |
| Q35071654 | Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature |
| Q55459845 | Successful treatment of recurrent preoperative bleeding of glioblastoma with recombinant activated factor VII: pathophysiological hypothesis. |
| Q89599684 | Surgery for spontaneous intracerebral hemorrhage |
| Q36297341 | Surgery versus Conservative Treatment for Spontaneous Supratentorial Intracerebral Hemorrhage in Spot Sign Positive Patients |
| Q52098871 | Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial. |
| Q38239106 | Surgical management in treatment of Jehovah's witness in trauma surgery in Indian subcontinent |
| Q34346921 | Surgical trials in intracerebral hemorrhage. |
| Q36399906 | Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: the spot sign score |
| Q33876266 | Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications |
| Q34028327 | Systemic hematologic status following intraventricular recombinant tissue-type plasminogen activator for intraventricular hemorrhage: the CLEAR IVH Study Group |
| Q28075902 | Targeting Secondary Hematoma Expansion in Spontaneous Intracerebral Hemorrhage - State of the Art |
| Q30833127 | The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. |
| Q40950987 | The HEP Score: A Nomogram-Derived Hematoma Expansion Prediction Scale |
| Q34570357 | The Modified Graeb Score: an enhanced tool for intraventricular hemorrhage measurement and prediction of functional outcome. |
| Q38591756 | The Neurocritical and Neurosurgical Care of Subdural Hematomas. |
| Q57781040 | The Second (Main) Phase of an Open, Randomised, Multicentre Study to Investigate the Effectiveness of an Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (Interact2) |
| Q34776423 | The accuracy of spot sign in predicting hematoma expansion after intracerebral hemorrhage: a systematic review and meta-analysis |
| Q37172710 | The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage |
| Q28067962 | The critical care management of spontaneous intracranial hemorrhage: a contemporary review |
| Q38915687 | The epidemic of pre-injury oral antiplatelet and anticoagulant use. |
| Q46549547 | The epidemiology of intracerebral hemorrhage in the United States from 1979 to 2008. |
| Q36537350 | The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework |
| Q37906398 | The neurocritical care research network: NCRN. |
| Q30532769 | The pattern and pace of hyperacute hemorrhage expansion |
| Q37873969 | The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. |
| Q33728350 | The role of tissue factor and factor VIIa in hemostasis |
| Q50694058 | The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. |
| Q34447657 | The spot sign predicts hematoma expansion, outcome, and mortality in patients with primary intracerebral hemorrhage |
| Q34272848 | The spot sign score in primary intracerebral hemorrhage identifies patients at highest risk of in-hospital mortality and poor outcome among survivors |
| Q37930462 | The surgical management of chronic subdural hematoma |
| Q37320480 | The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD) |
| Q35729599 | Therapeutic strategies in acute intracerebral hemorrhage |
| Q38764867 | Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke |
| Q38058024 | Therapy in pediatric stroke |
| Q33429614 | Therapy with blood products |
| Q33971455 | Thrombelastography detects possible coagulation disturbance in patients with intracerebral hemorrhage with hematoma enlargement |
| Q48461191 | Thrombin Causes Neuronal Atrophy and Acute but not Chronic Cell Death. |
| Q34513276 | Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study |
| Q36539797 | Time course and predictors of neurological deterioration after intracerebral hemorrhage |
| Q40475411 | Timing of INR reversal using fresh-frozen plasma in warfarin-associated intracerebral hemorrhage. |
| Q36839924 | Timing of Occurrence Is the Most Important Characteristic of Spot Sign |
| Q46755195 | Top 100 Most-Cited Articles on Spontaneous Intracerebral Hemorrhage: A Bibliometric Analysis |
| Q50747159 | Tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign trial: Rationale and design. |
| Q55395487 | Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. |
| Q35466780 | Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis |
| Q37590893 | Transcriptional and Genomic Targets of Neural Stem Cells for Functional Recovery after Hemorrhagic Stroke. |
| Q40405381 | Treatment of acute intracerebral hemorrhage |
| Q38541197 | Treatment of acute stroke: an update |
| Q43781422 | Treatment of acute subdural hematoma |
| Q37788997 | Treatment of coagulopathy in intracranial hemorrhage |
| Q35107082 | Treatment of diffuse alveolar hemorrhage secondary to lupus erythematosus with recombinant activated factor VII administered with a jet nebulizer |
| Q47553677 | Treatment of individuals who cannot receive blood products for religious or other reasons. |
| Q58438976 | Treatment of intracerebral haemorrhage with tranexamic acid – A review of current evidence and ongoing trials |
| Q44199174 | Treatment of intracerebral hemorrhage-is the glass half full or half empty? |
| Q33392785 | Treatment of intracerebral hemorrhage: what should we do now? |
| Q35648063 | Treatment targets in intracerebral hemorrhage |
| Q36449900 | Trends in the management of atrial fibrillation: A neurologist's perspective |
| Q37152242 | Tumor necrosis factor α antagonism improves neurological recovery in murine intracerebral hemorrhage |
| Q62312640 | Unmet Needs and Challenges in Clinical Research of Intracerebral Hemorrhage |
| Q37052828 | Update in intracerebral hemorrhage |
| Q48507011 | Update on the Treatment of Spontaneous Intraparenchymal Hemorrhage: Medical and Interventional Management. |
| Q40666980 | Use of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis |
| Q33581052 | Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury |
| Q34472516 | Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis |
| Q34033129 | Vascular disruption and blood-brain barrier dysfunction in intracerebral hemorrhage |
| Q48056225 | Web-Based Assessment of Outcomes After Subarachnoid and Intracerebral Hemorrhage: A New Patient Centered Option for Outcomes Assessment |
| Q38903679 | What are the next breakthroughs in the management of acute intracerebral hemorrhage? |
| Q38067628 | What does the CT angiography "spot sign" of intracerebral hemorrhage mean in modern neurosurgical settings with minimally invasive endoscopic techniques? |
| Q52656883 | Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. |
| Q50062218 | [Current treatment concepts in intracerebral hemorrhage]. |
| Q84134489 | [Full stop and continuing] |
| Q83694725 | [Intensive care management [corrected] of patients with intracerebral hemorrhage] |
| Q85525620 | [Management of intracerebral hemorrhage: can we still learn something?] |
| Q54127394 | [Oral anticoagulant-associated intracerebral haemorrhage]. |
| Q84134503 | [Recombinant activated factor VII for spontaneous cerebral hemorrhage] |
| Q83749473 | [Report from NeuroUpdate in Wiesbaden (13/14 February 2009)] |
| Q45963998 | [Reversal of acenocoumarol anticoagulation with activated factor VII in massive hemorrhage following rupture of a splenic artery pseudoaneurysm] |
| Q86939566 | [Traumatic brain injury in anticoagulated patients : Hemostatic therapy for the treatment of intracranial hemorrhage] |
| Q84509682 | [Use of activated recombinant factor VII in patients with brain injury or undergoing brain surgery] |
| Q38668253 | microRNAs in Cerebrovascular Disease. |
Search more.